How does everolimus contribute to immunosuppression following liver transplantation?

Updated: Dec 31, 2017
  • Author: Lemi Luu, MD, RDMS, FACEP, FAAEM; Chief Editor: Barry E Brenner, MD, PhD, FACEP  more...
  • Print


Everolimus is an mTOR kinase inhibitor that inhibits antigenic and interleukin (IL-2 and IL-15) stimulated activation and proliferation of T and B lymphocytes. It is indicated for prophylaxis of allograft rejection in adult liver transplant recipients in combination with reduced doses of tacrolimus and with corticosteroids. The use of mTOR inhibitors provides a calcineurin inhibitor-sparing regimen to avoid impaired renal function associated with tacrolimus or cyclosporine.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!